GLP-1 Agonists: The Weight Loss Revolution

What Is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut in response to eating. It serves several functions: it stimulates the pancreas to release insulin (when blood glucose is elevated), suppresses glucagon (which would otherwise raise blood sugar), slows gastric emptying (so you feel full longer), and signals the brain — specifically the hypothalamus — to reduce appetite.

GLP-1 is naturally short-lived. Enzymes called DPP-4 break it down within minutes of release. GLP-1 receptor agonists are drugs that mimic GLP-1's effects but are designed to resist DPP-4 degradation, lasting hours to weeks depending on the formulation.

How GLP-1 Agonists Work

GLP-1 agonists bind to and activate the GLP-1 receptor — they are agonists in the pharmacological sense, mimicking the action of the natural hormone with equal or greater potencyPotency

The amount of drug needed to produce a given effect. A more potent drug achieves the same effect at a lower dose. Potency is different from efficacy — a drug can be highly potent but have limited maxi

. The receptor is found in the pancreas, gut, heart, kidneys, and brain.

The weight loss effect appears to be primarily driven by central nervous system action: GLP-1 receptors in the brain reduce hunger signaling and increase satiety, leading people to eat less without conscious effort. The slowing of gastric emptying further reinforces the feeling of fullness after smaller meals.

At higher doses, the effect on brain appetite circuits is more pronounced, which is why formulations approved for weight loss (Wegovy, Zepbound) use higher doses than those approved for diabetes management alone (Ozempic, Victoza).

Approved Drugs in This Class

Semaglutide (Ozempic, Wegovy, Rybelsus) - Ozempic: once-weekly subcutaneousSubcutaneous

A route of drug administration where medication is injected into the layer of fat and connective tissue just beneath the skin. Absorption is slower than IV or IM but is suitable for self-administratio

injection, approved for type 2 diabetes - Wegovy: once-weekly subcutaneous injection, higher dose, approved for chronic weight management - Rybelsus: daily oral tablet for type 2 diabetes (the first oral GLP-1 agonistAgonist

A drug that binds to a receptor and activates it, producing a biological response that mimics the body's natural signaling molecules. Full agonists produce the maximum possible effect, while partial a

)

Tirzepatide (Mounjaro, Zepbound) - Dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor - Mounjaro: approved for type 2 diabetes - Zepbound: approved for chronic weight management

Older agents: Liraglutide (Victoza for diabetes, Saxenda for obesity), exenatide (Byetta, Bydureon), and dulaglutide (Trulicity) are earlier GLP-1 agonists with more modest weight effects.

Weight Loss Evidence

Clinical trials have produced results once thought impossible for pharmacotherapy:

• STEP 1 trial (semaglutide 2.4 mg): Participants lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo.
• SURMOUNT-1 trial (tirzepatide 15 mg): Average weight loss of 20.9% over 72 weeks — approaching the weight loss seen with bariatric surgery in some patients.
• SCALE trial (liraglutide 3.0 mg): Average 5.4% additional weight loss over placebo at one year.

Weight loss is maintained while taking the drug; most of the weight returns within a year of stopping, which has important implications for how clinicians discuss long-term treatment expectations with patients.

Cardiovascular and Metabolic Benefits

GLP-1 agonists have demonstrated cardiovascular benefits beyond glucose control and weight loss:

• The SELECT trial (semaglutide 2.4 mg) enrolled people with obesity and established cardiovascular disease but without diabetes, and showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death).
• LEADER and SUSTAIN-6 trials demonstrated cardiovascular risk reduction for liraglutide and semaglutide in people with type 2 diabetes.
• Emerging data suggest benefits for kidney disease progression, non-alcoholic fatty liver disease (MAFLD), and possibly obstructive sleep apnea.

These benefits appear to arise from multiple mechanisms — weight loss, direct vascular effects, anti-inflammatory signaling, and improvements in blood pressure and lipids.

Side Effects and Risks

The most common side effects are gastrointestinal: - Nausea (very common, especially when starting or escalating dose) - Vomiting, diarrhea, constipation - Belching, heartburn

These effects are often dose-dependent and tend to improve over weeks. Starting at a low dose and increasing gradually (dose escalation) reduces their severity.

More serious but rarer risks: - Pancreatitis: Inflammation of the pancreas; patients should report persistent severe abdominal pain. - Gallbladder disease: Rapid weight loss itself increases gallstone risk; GLP-1 agents may compound this. - Thyroid C-cell tumors: Seen in rodent studies at high doses; a boxed warning exists, and these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. - Muscle loss: Some of the weight lost is lean mass; resistance exercise and adequate protein intake are recommended to mitigate this.

Biosimilars and Access

Semaglutide and liraglutide are injectable biologics. As patents expire, biosimilarBiosimilar

A biologic drug that is highly similar to an already approved reference biologic product, with no clinically meaningful differences in safety, purity, or potency. Unlike generics (which are chemically

versions may reduce costs substantially. The FDA has an approval pathway for biosimilar biologics, and several manufacturers are developing biosimilar semaglutide. Tirzepatide is a synthetic peptide — competition from generic peptides is also anticipated.

The dose-response relationship with GLP-1 agonists is important: higher doses produce greater weight loss but also more side effects. Titrating to the highest tolerated dose (within the approved range) typically maximizes benefit.

Key Takeaways

• GLP-1 agonists mimic a natural gut hormone that reduces appetite, slows gastric emptying, and improves insulin secretion.
• Semaglutide and tirzepatide produce 15–21% average body weight reduction in trials — approaching surgical outcomes for some patients.
• Cardiovascular, renal, and metabolic benefits extend beyond weight loss.
• Nausea and GI side effects are common; rare but serious risks include pancreatitis and gallbladder disease.
• Weight typically returns after stopping; most patients require long-term or indefinite treatment.
• Biosimilars are in development and may improve affordability as patents expire.